跳到正文
原文
Medical Xpress·· 1 天前精选AI 评分67

brepocitinib在治疗皮肤嗜酸性肉芽肿性多血管炎方面有改善

Brepocitinib yields improvements in cutaneous sarcoidosis

AI 导读

一项针对皮肤嗜酸性肉芽肿性多血管炎的II期临床试验显示,brepocitinib在15毫克和45毫克剂量下均显著改善了疾病活动度,45毫克剂量组的疗效更优,支持剂量依赖性治疗效果。

推荐理由

研究显示brepocitinib在治疗皮肤嗜酸性肉芽肿性多血管炎方面有剂量依赖性疗效,支持进一步开发。

正文
Brepocitinib yields improvements in cutaneous sarcoidosis
Visual abstract. Credit: JAMA Dermatology (2026). DOI: 10.1001/jamadermatol.2026.5444

For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida.

Misha Rosenbach, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues examined the efficacy and safety of brepocitinib in adults with CS in the Phase II portion of a multicenter, randomized, placebo-controlled trial. Thirty-one patients were enrolled and were randomly assigned to receive brepocitinib 45 mg, brepocitinib 15 mg or placebo once daily.

The researchers observed a significant improvement in CS disease activity with both brepocitinib doses; Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) scores improved by 22.3 and 22.2 points in the 45-mg and 15-mg groups, respectively, versus 0.7 points with placebo by week 16. Efficacy consistently favored brepocitinib 45 mg across responder-based and cutaneous remission-oriented end points, supporting a dose-dependent treatment effect.

Brepocitinib 45 mg versus placebo resulted in higher rates of Cutaneous Sarcoidosis Activity-Investigator Global Assessment clear or almost clear disease, CSAMI-A response, ≥10-point CSAMI-A reduction and achievement of a CSAMI-A score <5. Clinical benefit extended to difficult-to-treat phenotypes and was accompanied by skin-related quality-of-life improvements.

"These published findings bring rigorous clinical evidence to a historically neglected disease and patient population and offer a compelling reason to believe that a fundamentally different future with more targeted, effective treatments may be possible for our patients," Rosenbach said in a statement.

Publication details

Misha Rosenbach et al., Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis, JAMA Dermatology (2026). DOI: 10.1001/jamadermatol.2026.5444

Journal information: JAMA Dermatology

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Copyright © 2026 HealthDay. All rights reserved.

Citation: Brepocitinib yields improvements in cutaneous sarcoidosis (2026, November 18) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-brepocitinib-yields-cutaneous-sarcoidosis.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com